Psylin Neurosciences Commences Development of Compound for ...(in vivo approach to drug discovery sai...)

Date:4/20/2009

in vivo approach to drug discovery," said Emer Leahy, Ph.D., Co-CEO of Psylin and President and CEO of PsychoGenics. "PSN0041 is a very exciting molecule that offers a new approach to the treatment of depression and based on our preclinical models is expected to provide certain unique advantages over existing treatments."

Psylin's mission is to pioneer the development of peptide therapeutics for the treatment of psychiatric disorders. PSN0041 will be the first compound in Psylin's pipeline to enter into clinical development. Other compounds are being investigated for development as antipsychotic and mood stabilizing therapies.

Amylin's proprietary peptide library known as PHORMOL encompasses an extensive panel of potentially valuable biologics that have been taken from nature, including human peptides not previously described. All of these have been synthesized to create a rich source of compounds that are being evaluated for potential utility in a range of diseases.

PsychoGenics' proprietary drug discovery technologies combine its broad in vivo behavioral expertise with recent developments in robotics, computer vision and bio/cheminformatics to evaluate drug candidates for potential utility across the spectrum of neuropsychiatric disease indications. Working in partnership with pharmaceutical and biotech companies, PsychoGenics has been instrumental in identifying therapeutic potential for a variety of early and late stage compounds including some with novel "first-in-class" mechanisms of action such as PSN0041.

About Depression

Depression is the leading major cause of disability in the United States. According to the National Institute of Mental Health, depression affects approximately 19 million people in the United States. The U.S. Surgeon General estimates that the indirect costs attributable to depression amount to $80 billion annually.

'/>"/>

SOURCE Psylin Neurosciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Intellect Neurosciences, Inc. Issues Letter to Shareholders From Its Chairman and CEO
2. Blanchette Rockefeller Neurosciences Institute Hosts First-Ever International Forum on Memory and Memory Disorders and Dedicates New $30 Million Research Facility
3. Intellect Neurosciences, Inc. Grants License for Certain Patents and Patent Applications to Wyeth and Elan Pharma International Ltd.
4. Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimers Disease
5. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
6. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
7. Amarin Signs Agreement to Acquire Ester Neurosciences
8. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
9. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
10. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
11. BioVex Commences OncoVEX (GM-CSF) Phase 3 Trial in Metastatic Melanoma